NEW YORK (GenomeWeb News) — Genetix last week said it has completed its acquisition of Applied Imaging.

 

Genetix plans to use the company’s protein biomarker hardware and software with its own ClonePix and CloneSelect Imager and reagents to “track the progress of drug discovery” from lab to clinic.

 

Applied Imaging’s Ariol instruments and CytoVision software are used to study tumors at the protein biomarker level to find targets, monitor responses, and predict the how a drug will work.